Drug company Mylan agreed to pay $465 million to quickly settle a Justice Department investigation into claims that it deliberately overcharged Medicaid for its EpiPen anti-allergy device. Why would a company agree so quickly to such a large settlement? Well, it might have something to do with this … The Department of Health and Human Services’ Office of Inspector General reports that the Medicaid misclassification of EpiPen may have cost taxpayers $1.27 billion from 2006 to 2016. Senator Richard Blumenthal and a group representing state Medicaid directors are now demanding that Mylan pay Medicaid the full amount up to $1.27 billion that it owes. Fortunately, the previous settlement agreement, which is a fraction of the true costs, has not yet been finalized.
On May 24 and 25, the Women Trial Lawyers Caucus descended on Capitol Hill to lobby Congress to beat back legislation designed to close the courthouse doors on our clients. Overall, 150 women from 41 states attended over 250 Congressional meetings.
Women trial lawyers stormed the Hill armed with their clients’ stories to oppose H.R. 1215—a draconian medical malpractice/drug, device, and nursing home bill and H.R. 985—a bill that would virtually end class actions and multidistrict litigation, and make it much harder for asbestos victims to obtain compensation through asbestos trusts.
These bills are just two out of more than 300 congressional bills AAJ is tracking so far this year. Each of these bills is harmful to consumers, patients, or workers, in some way. AAJ is always on the lookout for bills that infringe on civil justice. Among the bills AAJ is currently tracking is one that would have a profound effect on civil rights litigation by limiting the rights of victims of law enforcement violence.
The National Highway Traffic Safety Administration released a series of reports involving Takata’s defective air bag inflators, around 100 million of which have been declared defective worldwide, with nearly 70 million inflators in the U.S. alone. In the report, Takata also holds its U.S. arm, not the parent company, responsible for designing, testing and producing defective air bag inflators.
General Motors stated it will recall almost 4.3 million vehicles worldwide due to a software defect that prevents air bags from deploying during a crash, a fault already linked to one death and three injuries.